An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease.

Chamberlain S, Gabriel H, Strittmatter W, Didsbury J

J Alzheimers Dis. 2020; 73(3):1085-1103. PMID: 31884472. Abstract